2019 ISPE Biopharmaceutical Manufacturing Conference

18 - 20 June 

Thank you for making this conference a huge success!

The latest in the fast-moving journey—some call it a revolution—of biopharma development were well represented at the 2019 ISPE Biopharmaceutical Manufacturing Conference in Boston, MA on 18-20 June. The fourth annual conference drew more than 300 attendees, with 168 companies represented from 15 countries. They came together to learn about innovation in production methods and technologies that enable a competitive and sustainable biopharmaceutical product supply for the future—and the rapid changes that are bringing life-saving pharmaceuticals to patients in need.

The observation that this is “not your parents’ biopharma” was a theme of the three-day conference that addressed the latest developments in biopharma in plenary and concurrent breakout sessions. The next stage of the journey—into supply chain expansion and commercialization—highlighted the conference. Recent developments are being translated into therapies available to more patients, and keeping the patient in mind is most important for the industry, noted conference chair Andre Walker, CPIP, Principal, Walker BioPharm Consulting. 


conference attendees
John Bournas and attendees
ISPE team
Conference training
Andre L. Walker, CPIP
Steve Bagshaw, CEng, FIChemE
Conference Attendee
Jeffrey C. Baker, PhD
Speaker
Speaker
Attendee
Conference Attendees

  • 2019 ISPE Biopharmaceutical Manufacturing Conference Speaker
  • 2019 ISPE Biopharmaceutical Manufacturing Conference ISPE reps
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Vendor
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Speaker Panel
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Networking Event
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Networking Event
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Networking Event
  • 2019 ISPE Biopharmaceutical Manufacturing Conference John Bournas
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Networking Event
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Networking Event
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Speaker Panel
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Vivianne J. Arencibia
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendees
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendees
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee questions
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Christine M. V. Moore, PhD
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Carol Rocks
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Charles L. Cooney, PhD
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee questions
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Speaker panel
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Vendor
  • 2019 ISPE Biopharmaceutical Manufacturing Conference Attendee activity

Conference Highlights


Program Committee

Andre L. Walker, CPIP
Principal
Walker BioPharm Consulting
Chair
Darren M. Dasburg
Bio Executive
Self Employed
David Doleski
Compliance Head for Biologics Quality Operations
Sanofi
Kevin M. Chronley
Vice President
A/Z Corporation
Stephen C. Mahoney, JD
Senior Director, Global Quality & Compliance
Genentech
Antonio R. Moreira, PhD
Vice Provost, Academic Affairs
University of Maryland, Baltimore County
Jeffery N. Odum, CPIP
Head of Design, Technology & Standards, Biologics Engineering
Sanofi
Robert Dream, PE, CPIP
Principal
HDR Company LLC
Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates

Board Ambassador

Thomas B. Hartman
VP, GMP Operations
GlaxoSmithKline
Christine M. V. Moore, PhD
Global Head and Executive Director, GRACS CMC Policy
Merck & Co.